7
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T13688 | Eribulin | B1939,ER-086526,E7389 | Others |
Eribulin inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules. Eribulin is a microtubule targeting agent that is used in the treatment of metastatic breast cancer. | |||
T13687 | Eribulin mesylate | B1939 mesylate,ER-086526 mesylate,E7389 mesylate | Apoptosis , Others , Microtubule Associated |
Eribulin mesylate (E7389 mesylate) (E7389 mesylate) inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules. Eribulin mesylate (E7389 mesylate) is a microtubule targeting agent that is... | |||
T39579 | Mal-(CH2)5-Val-Cit-PAB-Eribulin | Mal-(CH2)5-Val-Cit-PAB-Eribulin | |
Mal-(CH2)5-Val-Cit-PAB-Eribulin is a potent antitumor ADC drug-linker conjugate that utilizes Eribulin, an anti-microtubule agent, connected through the Mal-(CH2)5-Val-Cit-PAB linker. | |||
T18871 | VCP-Eribulin | Others | |
VCP-Eribulin, an Eribulin-based drug for antibody conjugates[1], combines the VCP (ADCs linker) with Eribulin, a distinct microtubule inhibitor used in cancer treatments[2]. | |||
T18278 | Mal-PEG2-VCP-Eribulin | Others | |
Mal-PEG2-VCP-Eribulin is a chemotherapeutic compound comprising an antibody-drug conjugate (ADC) linker (Mal-PEG2-VCP) and the microtubule inhibitor Eribulin[1]. This compound uniquely targets microtubules, offering a no... | |||
T82323 | GGFG-Eribulin | ||
Eribulin-GGFG (Compound GGFG) is a drug-linker conjugate for antibody-drug conjugates (ADCs). Comprised of the cytotoxic agent exatecan and a connecting linker, it facilitates the synthesis of ADCs [1]. | |||
T77908 | Farletuzumab ecteribulin | MORAb-202 | |
Farletuzumab ecteribulin (MORAb-202) is a highly cytotoxic antibody-drug conjugate (ADC) targeting human folate receptor alpha (FRA). This ADC comprises the humanized Farletuzumab antibody linked to Mal-PEG2-Val-Cit-PAB-... |